Myeloma

Treatment with bb2121 showed promising efficacy and safety among heavily pretreated patients with multiple myeloma, according to interim results published in the New England Journal of Medicine.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

An expert discusses how CAR-T cells will fit into the treatment paradigm for patients with multiple myeloma in the future.

Although a reasonable and often curative treatment option, use of allogeneic hematopoietic stem cell therapy in relapsed multiple myeloma still tends to fall under the radar.

An expert discusses treating multiple myeloma with potential curative intent.

The Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 recommending the FDA delay approval of selinexor for the treatment of patients with penta-refractory multiple myeloma until further trial data are available.

Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.

Patients with multiple myeloma find relief from side effects, thanks to newer drug combinations.

Researchers are using innovative technology to hunt down hidden cancer cells.

The Food and Drug Administration (FDA) approved a split-dosing regimen for Darzalex (daratumumab) for the treatment of patients with multiple myeloma.

Obesity may be to blame for increasing rates of certain cancers in young adults.

Splitting up Darzalex dosing had comparable results to standard dosing schedules in patients with myeloma.

From World Cancer Day to top performers and athletes, here is a quick overview of what is making headlines in the cancer space.

Multiple myeloma is a type of blood cancer that originates in the bones. Here’s what you need to know about the disease.

All in all, I’m very pleased with being able to get my oral chemo directly from my clinic’s pharmacy. The staff knows me and they know my doctor.

Toronto’s Jeff Lipton, PhD, MD, FRCPC, shares his thoughts on the outlook for blood cancers.

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.

The combination of Darzalex (daratumumab), Revlimid (lenalidomide) and dexamethasone significantly reduced the risk for disease progression in patients with newly diagnosed multiple myeloma.

New findings could spark change in the way that some patients with multiple myeloma are treated.

Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!

In the general population, African Americans tend to have poorer myeloma outcomes; however, that may not be the case for veterans.

Hear patient-to-patient advice on navigating the complicated landscape of cancer care (and its costs).

"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

Treating people with cancer requires the coordination of complex care, and adding a clinical trial to the mix can pose more challenges.

A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.

Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.

The Food and Drug Administration has granted a priority review to a new drug application for selinexor (KPT-330) for the treatment of patients with penta-refractory multiple myeloma.

The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.